Harmony Biosciences (HRMY) is a public company. Harmony Biosciences is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for people living with rare and other neurological diseases with unmet medical needs.

Guided by empathy, driven by science, and focused on innovation, we combine a strong commercial foundation with a growing pipeline of differentiated programs designed to advance treatment across multiple neurological conditions. By creating long-term value through scientific innovation, operational excellence, and disciplined execution, we invest in our people, our pipeline, and our mission to help improve patients’ lives.

Follow us:​ Instagram → @harmony_biosciences​ X → @harmonybio​

#InHarmony #EmpathyAndInnovation ​

View community guidelines: http://bit.ly/4v2Exc8. Founded in 2017. It has 340 employees. Annual revenue is $868.5M. IPO 2020.

Transcript

Operator

Good morning, everyone. My name is Bo, I will be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences Second Quarter Financial Results Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speakers' prepared remarks, there will be a question and answer session. If you would like to ask a question at that time, please press star one on your telephone. Please be advised that today's conference is being recorded. Lastly, if you should require operator assistance today, please press star zero. I would now like to turn the call over to Mr. Brennan Doyle, Head of Investor Relations. Please go ahead, sir.

Brennan Doyle — Head of Investor Relations

Good morning, everyone, thank you for joining us today as we review Harmony Biosciences second quarter 2026 financial results and provide a business update. Before we start, I encourage everyone to go to the investor section of our website to find the materials that accompany today's discussion, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO, Adam Zaeske, Chief Commercial Officer, Dr. Kumar Budur, Chief Medical and Scientific Officer, Peter Anastasiou, Chief Operating Officer, and Stephen Mollichella, Interim